On March 16, 2021, Solid Biosciences joined PPMD for a webinar to provide a safety and efficacy update on the ongoing IGNITE DMD phase I/II clinical study of SGT-001 microdystrophin gene therapy in patients with Duchenne muscular dystrophy. Research & Clinical Trial Webinars,Webinars 4 years ago You may also like 29:46 Update on Investigational Suvodirsen in Duchenne Muscular Dystrophy (December 2019) 5 years ago Research & Clinical Trial Webinars,Webinars 1:17:48 Better Todays. Stronger Tomorrows. (December 2019) 5 years ago Care Webinars,Research & Clinical Trial Webinars,Webinars 35:37 NS Pharma Provides Viltolarsen Update (November 2019) 5 years ago Research & Clinical Trial Webinars,Webinars 47:13 DYSTANCE 51, a Phase 2/3 Clinical Trial of Investigational Suvodirsen in Duchenne (October 2019) 5 years ago Research & Clinical Trial Webinars,Webinars 52:44 Community Discussion with Sarepta Therapeutics (August 2019) 5 years ago Research & Clinical Trial Webinars,Webinars 18:32 Adaptive Sports (August 2019) 5 years ago For Teens & Adults,PPMD Adult Advisory Committee (PAAC) Webinars,Webinars 57:50 Capricor’s HOPE-2 Interim Analysis (July 2019) 5 years ago Research & Clinical Trial Webinars,Webinars 36:52 Rolling Around the World (June 2019) 5 years ago For Teens & Adults,PPMD Adult Advisory Committee (PAAC) Webinars,Webinars «1…1213141516…25»Page 14 of 25
by: Parent Project Muscular Dystrophy
